REFERENCES
- Ayliffe G. A. The progressive intercontinental spreads of methicillin-resistantStaphylococcus aureus. Clin. Infect. Dis. 1997; 24(Suppl 1)S74–S79, [PUBMED], [INFOTRIEVE]
- Bergsson G., Arnfinnsson J., Karlsson S. M., Steingrimsson O., Thormar H. In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides. Antimicrob. Agents Chemotherap. 1998; 42: 2290–2294, [CSA]
- Burnie J., Matthews R., Jiman-Fatami A., Gottardello P., Hodgetts S., D'arcy S. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistantStaphylococcus aureus: Evidence of resistance to vancomycin. Clin. Infect. Dis. 2000; 31: 684–689, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Carson C. F., Cookson B. D., Farrelly H. D., Riley T. V. Susceptibility of methicillin resistantStaphylococcus aureusto the essential oil of Melaleuca alternifolia. J. Antimicrob. Chemother 1995; 35: 421–424, [PUBMED], [INFOTRIEVE], [CSA]
- Conley A. J., Kabara J. J. Antimicrobial action of esters of polyhydric alcohols. Antimicrob. Agents Chemother. 1973; 4: 501–506, [PUBMED], [INFOTRIEVE]
- Cunha B. A. Strategies to control antibiotic resistance. Semin. Respir. Infect. 2002; 17: 250–258, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Denis O., Nonhoff C., Byl B., Knoop C., Bobin-Dubreux S., Struelens M. J. Emergence of vancomycin-intermediateStaphylococcus aureusin a Belgian hospital: Microbiological and clinical features. J. Antimicrob. Chemother 2002; 50: 383–391, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Edmond M. B., Wenzel R. P., Pasculle A. W. Vancomycin-resistantStaphylococcus aureus: Perspectives on measures needed for control. Ann. Intern. Med 1996; 124: 329–334, [PUBMED], [INFOTRIEVE], [CSA]
- Hammer K. A., Carson C. F., Riley T. V. Antimicrobial activity of essential oils and other plant extracts. J. Appl. Microbiol. 1999; 86: 985–990, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hiramatsu K., Hanake H., Ino T., Yabuta K., Oguri T., Tenover F. C. Methicillin-resistantStaphylococcus aureusclinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother 1997; 40: 135–136, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hitokoto H., Morozumi S., Wauke T., Sakai S., Kurata H. Inhibitory effects of spices on growth and toxin production of toxigenic fungi. Appl. Environ. Microbiol. 1980; 39: 818–822, [PUBMED], [INFOTRIEVE]
- Ingram C. The cures. LifeSaving Cure. How to Use the Latest & Most Powerful Cures for the 21st Century. Knowledge House Publishers, Buffalo Grove, IL 2000; 251–252
- Isaacs C. E., Kashyap S., Heird W. C., Thormar H. Antiviral and antibacterial lipids in human milk and infant formula feed. Arch. Dis. Child. 1991; 65: 272–273
- Isaacs C. E., Thormar H. The role of milk-derived antimicrobial lipids as antiviral and antibacterial agents. Adv. Exp. Med. Biol. 1991; 310: 159–165, [PUBMED], [INFOTRIEVE]
- Ismaiel A., Pierson M. D. Inhibition of growth and germination of C botulinum 33A, 40B, and 1623E by essential oil of spices. J. Food Sci. 1990; 55: 1676–1680
- Kabara J. J. Lipids as host-resistance factors of human milk. Nutr. Rev. 1980; 38: 65–73, [PUBMED], [INFOTRIEVE]
- Kabara J. J., Vrable R. Antimicrobial lipids: Natural and synthetic acids and monoglycerides. Lipids 1977; 12: 753–759, [PUBMED], [INFOTRIEVE]
- Kim J., Marshall M. R., Wei C.-I. Antibacterial activity of some essential oil components against five foodborne pathogens. J. Agric. Food Chem. 1995; 43: 2839–2845, [CROSSREF], [CSA]
- Kivanc M., Akgul A., Dogan A. Inhibitory and stimulatory effects of cumin, oregano and their essential oils on growth and acid production ofLactobacillus plantarumandLeuconostoc mesenteroides. Int. J. Food Microbiol 1991; 13: 81–86, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Manohar V., Ingram C., Gray J., Talpur N., Echard B. W., Bagchi D., Preuss H. G. Antifungal activities of Origanum oil against Candida albicans. Mol. Cell. Biochem. 2001; 228: 111–117, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mansour M., Bouttefroy A. D., Linder M., Milliere J. B. Inhibition of Bacillus licheniformis spore growth in milk by nisin, monolaurin and pH combinations. J. Appl. Microbiol. 1999; 86: 311–324, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Projan S. J., Brown-Skrobot S., Schlievert P. M., Vandenesch F., Novick R. P. Glycerol monolaurate inhibits the production of B-lactamase, toxic shock syndrome toxin-1, and other Staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol. 1994; 176: 4204–4209, [PUBMED], [INFOTRIEVE]
- Rex J. H., Pfaller M. S., Galgiani J. N., Bartlett M. S., Espinel-Ingroff A., Ghannoum M. A., Lancaster M., Odds F. C., Rinaldi M. G., Walsh T. J., Barry A. L. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole and itraconazole, and Candida infections. Clin. Infect. Dis. 1997; 24: 235–247, [PUBMED], [INFOTRIEVE], [CSA]
- Ruzin A., Novick R. P. Glycerol monolaurate inhibits induction of Vancomycin resistance in Enterococcus faecalis. J. Bacteriol. 1998; 180: 182–185, [PUBMED], [INFOTRIEVE]
- Ruzin A., Novick R. P. Equivalence of lauric acid and glycerol monolaurate as inhibitors of signal transduction inStaphylococcus aureus. J. Bacteriol 2000; 182: 2668–2671, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schlievert P. M., Deringer J. R., Kim M. H., Porjan S. J., Novick R. P. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob. Agents Chemother. 1992; 36: 626–631, [PUBMED], [INFOTRIEVE], [CSA]
- Shadomy S., Espinel-Ingroff A., Cart W. R. Laboratory studies with antifungal agents: Susceptibility test and bioassays. Manual Clin. Microbiol.4, E. H. Lennette, A. Ballows, W. J. Hausler, et al. American Society for Microbiology, Washington 1985; 991–999
- Siddiqui Y. M., Ettayebi M., Haddad A., Al-Ahdal M. N. Effect of essential oils on enveloped viruses: Antiviral activity of oregano and clove oils on herpes simplex virus type 1 and Newcastle disease virus. Med. Sci. Res. 1996; 24: 185–186
- Sieradzki K., Roberts R. B., Haber S. W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus infection. N. Engl. J. Med. 1999; 340: 517–523, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sivropoulus A., Papanikolaou E., Nikolaou C., Kokkini S., Lanaras T., Arsenakis M. Antimicrobial and cytoxic activities of Origanum essential oils. J. Agric. Food Chem. 1996; 44: 1202–1205, [CROSSREF], [CSA]
- Thormar H., Isaacs C. E., Brown H. R., Barshatzky M. R., Pessolano T. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob. Agents Chemother 1987; 31: 27–31, [PUBMED], [INFOTRIEVE], [CSA]
- U.S. Congress, Office of Technology Assessment. Impacts of antibiotic resistant bacteria. US Government Printing Office, Washington, DC 1995, OTA-H-629
- Waldvogel W. New resistance inStaphylococcus aureus. N. Eng. J. Med. 1999; 340: 556–557, [CROSSREF], [CSA]